Table 1.
Demographical and clinical characteristics of patients
| Patient | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|
| Age (years) | 47 | 52 | 39 | 31 | 34 | 32 |
| Sex | female | male | female | female | female | female |
| Disease duration (months) | 203 | 309 | 165 | 105 | 89 | 167 |
| Prior therapies | IFN-beta1b |
IFN-beta1a s.c.; IFN-beta1a i.m.; cyclophosphamide |
None | None | fingolimod | IFN-beta1a i.m. |
| N of relapses at MS diagnosis | 3 | 2 | 2 | 2 | 3 | 2 |
| N of relapses in the year before starting NTZ | 1 | 2 | 2 | 2 | 1 | 1 |
| N of relapses during NTZ | 0 | 0 | 0 | 0 | 0 | 0 |
| EDSS at onset | 4.5 | 2.5 | 3.5 | 1.0 | 1.5 | 6.0 |
| EDSS before at NTZ initiation | 5.0 | 2.0 | 3.5 | 0.0 | 1.5 | 4.0 |
| EDSS before COVID infectiona | 5.0 | 4.5 | 3.5 | 0.0 | 0.0 | 6.0 |
| N of new/enlarged/Gd-enhanced lesions at MS diagnosis | 0 | 0 | 0 | 2 | 3 | 4 |
| N of new/enlarged/Gd-enhanced lesions at NTZ initiation | 0 | 0 | 0 | 0 | 0 | 1 |
| N of new/enlarged/Gd + −enhanced lesions before COVID-19a | 0 | 0 | 0 | 0 | 0 | 0 |
| N of new/enlarged/Gd + −enhanced lesions after COVID-19b | 0 | 0 | 0 | 0 | 0 | 0 |
| N of NTZ administrations before COVID-19 | 28 | 69 | 18 | 13 | 57 | 62 |
| JCV statusa | negative | negative | positive (1.07) | negative | negative | negative |
| Comorbidities | none | myxoid liposarcoma c | none | none | none | none |
| Smoker | no | yes | no | yes | no | no |
| BMI | 21.6 | 25.6 | 24.3 | 27.1 | 21.3 | 25.0 |
COVID-19: Coronavirus Disease 2019; MS: Multiple Sclerosis; NTZ: natalizumab, IFN: interferon; s.c.: subcutaneously administered; i.m.: intramuscularly administered; EDSS: Expanded Disability Status Scale; Gd: gadolinium; JCV: John Cunningham virus; BMI: body mass index
aat last follow-up before COVID-19
b performed after recovery from COVID-19
csurgically treated in December 2015